Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study.
- Ruediger B Mueller,
- Winfried Graninger,
- Páris Sidiropoulos,
- Christoph Goger,
- Johannes von Kempis
Clin Rheumatol 2017 Aug 3. Epub 2017 Aug 3.
Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland.